Abstracts tagged "Outcome measures"

Abstract Number: 0427 • ACR Convergence 2020
Validation of Physician Global Assessment as an Outcome Measure in Relapsing Polychondritis
Emily Rose¹, Marcela Ferrada¹, Kaitlin Quinn², Wendy Goodspeed¹, Laurent Arnaud³ and Peter C. Grayson⁴, ¹Systemic Autoimmunity Branch, Vasculitis Translational Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, BETHESDA, MD, ²Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Washington, DC, ³Department of rheumatology, University Hospitals of Strasbourg and French National Reference Center for Rare Auto-immune diseases, Strasbourg, Alsace, France, ⁴Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, MD
Background/Purpose: Relapsing polychondritis (RP) is a rare systemic inflammatory disorder of cartilage that lacks validated disease activity measures. Physician global assessment (PhGA) is a measure…
Abstract Number: 0886 • ACR Convergence 2020
Achievement of Partial Remission and Inactive Disease in Upadacitinib-Treated Patients with Ankylosing Spondylitis
Atul Deodhar¹, Andrew Östör², Anna Maniccia³, Fabiana Ganz⁴, Tianming Gao³, Alvina D. Chu⁵ and Denis Poddubnyy⁶, ¹Oregon Health & Science University, Portland, OR, ²Cabrini Medical Center, Monash University, Malvern, Victoria, Australia, ³AbbVie Inc., North Chicago, IL, ⁴AbbVie Inc., Baar, Switzerland, ⁵AbbVie, North Chicago, IL, ⁶Charité – Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Assessment of SpondyloArthritis international Society (ASAS) response criteria and AS Disease Activity Score (ASDAS) are both commonly used, rigorous composite indices consisting of components…
Abstract Number: 1457 • ACR Convergence 2020
Two Minute Walking Distance and Other Timed Function Tests Are Superior to MMT-8 in Assessing Outcomes in Polymyositis and Dermatomyositis
Sai kumar Dunga¹, Chengappa G Kavadichanda² and VS Negi², ¹Jawaharlal institute of postgraduate medical education and research, puducherry, India, ²Jawaharlal institute of postgraduate medical education and research, Puducherry, Puducherry, India
Background/Purpose: Inflammatory myositis are heterogenous group of diseases affecting skeletal muscles and multiple different organs. Assessing improvement in disease activity is done by Manual muscle…
Abstract Number: 1726 • ACR Convergence 2020
Assessment of the Components of RAPID3 Patient Reported Outcomes in an Community Rheumatology Practice
Elston He¹, Pratyusha Yalamanchi², William Arnold³ and Erin Arnold⁴, ¹Synovium, Inc., Philadelphia, PA, ²Michigan Medicine, Ann Arbor, MI, ³Retired, Wilmette, IL, ⁴Private Practice, Orthopaedics and Rheumatology of the North Shore, Wilmette, IL
Background/Purpose: Patient reported outcomes are integral to measuring patient response to treatment for rheumatoid arthritis (RA). RAPID3 is a patient reported outcome metric that consists…
Abstract Number: 2013 • ACR Convergence 2020
Substantial Lifetime Risk of Developing Ankylosing Spondylitis (Axial Spondyloarthritis) for Relatives. Evidence from a 35-Year Follow-up Family Study of a Swiss Cohort
Sjef van der Linden¹, Peter Villiger², Zhixiu Li³, Matthew Brown⁴, Heinz Baumberger⁵, Hermine Zandwijk⁶ and Muhammad Khan⁷, ¹Department of Rheumatology, Immunology and Allergology, University of Bern, Inselspital, Bern, Switzerland, Mortroux, Belgium, ²Department of Rheumatology, Immunology and Allergology, University of Bern, Inselspital, Switzerland, Bern, Switzerland, ³Queensland University of Technology (QUT), Translational Genomics Group, School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Translational Research Institute, Princess Alexandra Hospital, Brisbane, Qld, Australia, Brisbane, Queensland, Australia, ⁴Guy's and St Thomas, NHS Foundation Trust and King's College London NIHR Biomedical Research Centre, King's College London, London, United Kingdom, London, United Kingdom, ⁵Retired, Flims, Tajikistan, ⁶Retired, Mortroux, Belgium, ⁷Case Western Reserve University, Cleveland OH, Westlake, OH
Background/Purpose: Familial occurrence of ankylosing spondylitis (AS) is well known. Our follow-up study aimed at assessing the incidence of clinically defined AS among first degree…
Abstract Number: 0250 • ACR Convergence 2020
Lupus Nephritis and Renal Outcomes in African-Americans: The Accelerating Medicines Partnership Cohort Experience
Andrea Fava¹, Jessica Li¹, Philip Carlucci², David Wofsy³, Judith James⁴, Chaim Putterman⁵, Betty Diamond⁶, Derek Fine⁷, Jose Monroy-Trujillo⁷, Kristin Haag⁷, Kristina Deonaraine⁸, The Accelerating Medicines Partnership in SLE Network⁹, William Apruzzese¹⁰, Jill Buyon¹¹ and Michelle Petri¹², ¹Johns Hopkins University, Baltimore, MD, ²New York University School of Medicine, New York, NY, ³University of California San Francisco, San Francisco, CA, ⁴Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation;Department of Pathology, University of Oklahoma Health Sciences Center;Department of Medicine, University of Oklahoma Health Sciences Center, Edmond, OK, ⁵Albert Einstein College of Medicine, Bronx, NY, ⁶Northwell Health, Manhasset, NY, ⁷Johns Hopkins University, Baltimore, ⁸New York University School of Medicine, New York, ⁹Multiple Institutions, Multiple Cities, ¹⁰., Boston, ¹¹Department of Medicine, NYU School of Medicine, New York, NY, ¹²Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: The Accelerating Medicines Partnership (AMP) will use multi-omics modalities including single cell RNA sequencing to understand lupus nephritis with the ultimate goal to devise…
Abstract Number: 0482 • ACR Convergence 2020
Differential Influence of CDAI Components Based on Disease State in Rheumatoid Arthritis Patients: Real World Results from a Rheumatoid Arthritis Cohort
Edward C Keystone¹, Mohammad Movahedi², Angela Cesta³, Claire Bombardier⁴, John Sampalis⁵ and Emmanouil Rampakakis⁵, ¹Mount Sinai Hospital, Toronto, ON, Canada, ²Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ³Toronto General Hospital Research Institute, Toronto, ON, Canada, ⁴Institute for Work and Health, Toronto, ON, Canada, ⁵JSS Medical Research, St-Laurent, QC, Canada
Background/Purpose: Treat-to-target recommendations for rheumatoid arthritis (RA) dictate that remission or low disease activity should be aimed. Although numerous composite indices are available, the clinical…
Abstract Number: 0896 • ACR Convergence 2020
Impact of Upadacitinib on Reducing Pain in Patients with Active Psoriatic Arthritis: Results from Two Phase 3 Trials in Patients with Inadequate Response to Non-biologic or Biologic DMARDs
Iain McInnes¹, William Tillett², Philip Mease³, Kurt de Vlam⁴, Louis Bessette⁵, Ralph Lippe⁶, Anna Maniccia⁷, Patrick Zueger⁷, Dai Feng⁷, Koji Kato⁸ and Andrew Östör⁹, ¹Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, ²Royal National Hospital for Rheumatic Diseases, Bath, UK; Department of Pharmacy and Pharmacology, University of Bath, Bath, UK, Bath, United Kingdom, ³Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ⁴Department of Rheumatology, University of Leuven, Belgium, Leuven, Belgium, ⁵Laval University, Quebec, Canada, ⁶AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany, ⁷AbbVie Inc., North Chicago, IL, ⁸AbbVie Inc, North Chicago, IL, ⁹Cabrini Medical Center, Monash University, Malvern, Victoria, Australia
Background/Purpose: Pain is a dominant symptom of psoriatic arthritis (PsA), and pain reduction is a priority for patients (pts) that is often assessed in clinical…
Abstract Number: 1490 • ACR Convergence 2020
Pain Rating Variability and Response to Treatment in Osteoarthritis Clinical Trials
Camila Pinto¹, Joana Barroso² and Thomas Schnitzer³, ¹Department of Physiology, Northwestern University Feinberg School of Medicine, Chicago, IL, ²Department of Physiology, Northwestern University, Feinberg School of Medicine, Chicago, IL, ³Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: Despite the known high inter- and intra-patient variability in analgesic responses in chronic pain, most interventional pain studies rely on single time point pain…
Abstract Number: 1731 • ACR Convergence 2020
Development of a Disease Activity Index for Rheumatoid Arthritis Patients Using the HandScan
Maxime Verhoeven¹, Paco Welsing¹, Janneke Tekstra¹, Jacob van Laar¹, Floris Lafeber¹, Johannes Jacobs¹ and Anton Westgeest², ¹UMC Utrecht, Utrecht, Netherlands, ²Máxima MC Eindhoven, Eindhoven, Netherlands
Background/Purpose: Disease activity in rheumatoid arthritis (RA) patients is usually measured by an index like DAS28,1 a composite measure consisting of 28 swollen and/or tender…
Abstract Number: 2031 • ACR Convergence 2020
Which Disease Activity Outcome Measure Discriminates Best in Axial Spondyloarthritis? A Systematic Literature Review and Meta-analysis
Augusta Ortolan¹, Victoria Navarro-Compán², Alexandre Sepriano³, Robert Landewé⁴, Désirée van der Heijde⁵ and Sofia Ramiro⁶, ¹Leiden University Medical Center, Padova, Italy, ²Hospital Universitario La Paz IdiPaz, Madrid, Pais Vasco, Spain, ³Leiden University Medical Center, Portela Loures, Portugal, ⁴Amsterdam University Medical Center & Zuyderland Hospital, Amsterdam, Netherlands, ⁵Leiden University Medical Center, Leiden, Netherlands, ⁶Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: Several disease activity response and status criteria are used to assess treatment efficacy in RCTs in axial spondyloarthritis (axSpA). Response criteria include: the Assessment…
Abstract Number: 0255 • ACR Convergence 2020
Effect of Removing Haemolytic and Gastrointestinal Activity from the Operational Definition of the Lupus Low Disease Activity State – Implications for Use as a Trial Endpoint
Vera Golder¹, Rangi Kandane-Rathnayake¹, Molla Huq², Worawit Louthrenoo³, Shue Fen Luo⁴, Yeong-Jian Wu⁵, Aisha Lateef⁶, Sargunan Sockalingam⁷, Sandra Navarra⁸, Leonid Zamora⁹, Laniyati Hamijoyo¹⁰, Yasuhiro Katsumata¹¹, Masayoshi Harigai¹², Madelynn Chan¹³, Sean O'Neill¹⁴, Fiona Goldblatt¹⁵, Chak Sing Lau¹⁶, Zhanguo Li¹⁷, Alberta Hoi¹⁸, Mandana Nikpour¹⁹ and Eric Morand²⁰, ¹Monash University, Clayton, Victoria, Australia, ²University of Melbourne, Melbourne, Victoria, Australia, ³Maharaj Nakorn Chiangmai, Muang, Thailand, ⁴Chang Gung Memorial Hospital-Linkou, Taoyuan, Taipei, Taiwan (Republic of China), ⁵Chang Gung Memorial Hospital, Guishan, Taiwan (Republic of China), ⁶National University Hospital, Singapore, Singapore, ⁷University of Malaya, Kuala Lumpur, Malaysia, ⁸University of Santo Tomas, Manila, Philippines, ⁹University of Santo Thomas, Manila, Philippines, ¹⁰University of Padjadjaran, Bandung, Indonesia, ¹¹Tokyo Women's Medical University School of Medicine, Tokyo, Japan, ¹²Department of Rheumatology, Tokyo Women’s Medical University School of Medicine, Shinjuku-ku, Tokyo, Japan, ¹³Tan Tock Seng Hospital, Singapore, Singapore, ¹⁴Sydney University, Sydney, Australia, ¹⁵Royal Adelaide Hospital, Adelaide, Australia, ¹⁶Hong Kong University, Hong Kong, Hong Kong, ¹⁷Department of Rheumatology and Immunology, Peking University People’s Hospital, Beijing, China (People's Republic), ¹⁸Monash University, Melbourne, Victoria, Australia, ¹⁹The University of Melbourne at St. Vincent's Hospital, Melbourne, Victoria, Australia, ²⁰Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia
Background/Purpose: The Lupus Low Disease Activity State (LLDAS) has recently undergone prospective longitudinal validation in a multinational cohort, demonstrating the association of attaining LLDAS with…
Abstract Number: 0514 • ACR Convergence 2020
Feasibility of 18F-fluorodeoxyglucose Positron Emission Tomography to Monitor the Effect of Tocilizumab on Vascular Inflammation in Giant Cell Arteritis: A Prospective Observational Cohort Study
Kaitlin Quinn¹, Himanshu Dashora², Mark Ahlman³, Elaine Novakovich² and Peter C. Grayson², ¹Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, ²Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, MD, ³National Institutes of Health, Clinical Center, Radiology and Imaging Sciences, Bethesda, MD
Background/Purpose: Two randomized controlled trials have demonstrated the clinical efficacy of tocilizumab for treatment of giant cell arteritis (GCA) (1,2). In these trials, response to…
Abstract Number: 0909 • ACR Convergence 2020
Residual Disease Activity in Psoriatic Arthritis Patients Treated with Secukinumab and Adalimumab Who Achieved Remission or Low Disease Activity: Results from a Phase 3b, Randomized, Double-blinded, Active-controlled, Head-to-head Study
Iain McInnes¹, Philip Mease², Dafna Gladman³, Laura Coates⁴, Peter Nash⁵, Alexis Ogdie⁶, Frank Behrens⁷, Philippe Goupille⁸, Arthur Kavanaugh⁹, Ruvie Martin¹⁰, Erhard Quebe-Fehling¹¹ and Corine Gaillez¹¹, ¹Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, ²Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ³Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁴University of Oxford, Oxford, United Kingdom, ⁵School of Medicine Griffith University, Brisbane, Queensland, Australia, ⁶University of Pennsylvania, Philadelphia, PA, ⁷CIRI/Rheumatology & Fraunhofer IME, Research Division Translational Medicine and Pharmacology, Goethe University Hospital, Frankfurt, Hessen, Germany, ⁸CHU Tours, department of rheumatology, Tours, France, ⁹Division of Rheumatology, Allergy, & Immunology, University of California San Diego Medical School, San Diego, CA, ¹⁰Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹¹Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Recent EULAR recommendations propose that treatment of psoriatic arthritis (PsA) should seek remission (REM) or alternatively low disease activity (LDA) by regular disease activity…
Abstract Number: 1585 • ACR Convergence 2020
Lessons Learned Through Rapid Quality Improvement for Telehealth Implementation in an Academic Rheumatology Practice During the COVID-19 Pandemic
Julie Thomas¹, Dorota Lebiedz-Odrobina¹, Kyle Register¹, Francesca Ferrara¹, Danielle Barlow¹, Alicia Riddle¹ and Karla Miller², ¹University of Utah, Salt Lake City, UT, ²Veterans Affairs Salt Lake City Health Care System, Salt Lake City, UT
Background/Purpose: The COVID-19 pandemic created an urgent need for access to care while preserving patient safety through social distancing. Prior to the pandemic, patients were…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].